Proteins commonly known as BRCA - short for BReast CAncer susceptibility gene- serve a critical role in cellular DNA repair, but when mutated they allow genetic errors to replicate, facilitating cancer development. If the BRCA repair system is disabled in cancer cells, the cells simply turn to backup repair mechanisms and adapt to alternative repair pathways, a survival mode that also underlies their ability to evade targeted drug therapies.
Now, new research by scientists shows that it is possible to eliminate at least two backup repair mechanisms at the same time using two targeted therapies. The strategy effectively narrows down the number of secondary repair pathways available, helping to ensure cancer cell eradication.
The novel approach, described in a paper published in Cell Reports, is named dual synthetic lethality, so-called because cancer cell death is induced by two drugs targeting distinct DNA repair pathways at the same time. "Cancers cells have multiple ways of protecting themselves from death," explained senior investigator.
Tumor cells that carry BRCA-deficiency mutations frequently rely on DNA repair mediated by a protein known as PARP1. Clinically, PARP1 inhibition can significantly improve progression-free survival in patients with cancers involving hereditary BRCA mutations.
Over time, however, the effectiveness of PARP1 inhibition declines, and cancer relapses. According to the senior author, this happens because targeting one pathway is not enough. "The tumor cells eventually escape PARP1 inhibition by activating another backup to the BRCA-mediated repair pathway," senior author said. "Our previous work had suggested that RAD52-dependent pathways are a likely escape route, which led us to see whether simultaneous inhibition of both PARP1 and RAD52 could trigger more effective lethality."
The team first tested their idea in a series of experiments in BRCA-deficient solid tumor and leukemia cell lines in vitro. Using an experimental RAD52 inhibitor, they were able to show that RAD52 blockade enhanced synthetic lethal effects in cells treated with the PARP inhibitor olaparib, a drug approved by the Food and Drug Administration. For all tumor types, the dual treatment completely eradicated BRCA-deficient tumor cells.
The simultaneous targeting strategy was then tested against BRCA-deficient tumors in mice, in which the researchers recapitulated the effects of BRCA deficiency in breast cancer and in acute and chronic myelogenous leukemia. They found that dual inhibition exerted strong effects against tumors in vivo, showing greater activity than either agent alone.
Importantly, the teams' experiments showed, both in vitro and in vivo, that normal cells, with normal BRCA activity, are unaffected by the dual treatment. "Normal cells continue to use BRCA-mediated repair as their primary DNA repair pathway and do not rely heavily on PARP1 or RAD52," explained first author on the new paper. Leaving normal cells relatively unharmed helps limit the severity of side effects patients may experience with targeted cancer therapy.
The new research provides a foundation for pursuing the development of a clinically viable drug to inhibit RAD52, as well as the development of a screening test specifically for patients who carry tumors displaying BRCA-deficiency.
In the near-term, the team also plans to continue investigating alternative DNA repair pathways, which are essential for tumor cells but expendable in normal cells. "One of our primary goals is to find additional targets to kill cancer cells, without increasing toxicity," senior author added.
https://www.templehealth.org/News/TempleScientistsEradicateCancerCellsThroughDualTargetingofDNARepairMechanisms?id=3243&showBack=true&PageIndex=0&cid=3
https://www.cell.com/cell-reports/fulltext/S2211-1247(18)30780-0
Targeting redundant DNA repair mechanisms to kill cancer cells!
- 2,788 views
- Added
Edited
Latest News
Brain hormone regulate both…
By newseditor
Posted 17 Mar
Blocking long non-coding RN…
By newseditor
Posted 17 Mar
Artificial intelligence and…
By newseditor
Posted 17 Mar
Blood-brain barrier protein…
By newseditor
Posted 17 Mar
Preventing heart attacks an…
By newseditor
Posted 17 Mar
Other Top Stories
Linking La Niņa climate cycle to increased diarrhea
Read more
Lead exposure linked to decreased brain volume in adolescents
Read more
How psychedelics may enhance mood at mass gatherings
Read more
New insights into neurobiology of decision-making and imagination
Read more
The pheromone darcin drives a circuit for innate and reinforced beh…
Read more
Protocols
Integration of Kupffer cell…
By newseditor
Posted 18 Mar
A mouse DRG genetic toolkit…
By newseditor
Posted 17 Mar
An optogenetic method for t…
By newseditor
Posted 13 Mar
Profiling native pulmonary…
By newseditor
Posted 08 Mar
Neuromuscular organoids mod…
By newseditor
Posted 06 Mar
Publications
Synaptopathy: presynaptic c…
By newseditor
Posted 18 Mar
Allergic Rhinitis
By newseditor
Posted 18 Mar
ALK upregulates POSTN and W…
By newseditor
Posted 18 Mar
PRODH safeguards human naiv…
By newseditor
Posted 18 Mar
Secretin-dependent signals…
By newseditor
Posted 17 Mar
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar